Instruction for use: Vaccinum grypposum inactivatum fluidum eluatum-centrifugatum

Dosage form: Subcutaneous suspension

Active substance: Vaccinum ad prophylaxim grippi inactivatum

ATX

J07BB01 Influenza virus inactivated whole

Pharmacological group

Vaccines, serums, phages and toxoids

The nosological classification (ICD-10)

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

Compositionand release form

1 inoculation dose (0.5 ml) contains 10 +, - 1 μg hemagglutinin of influenza A (H1N1) virus; 10 +, - 1 μg hemagglutinin of influenza A (H3N2) and 13 +, - 1 μg hemagglutinin of influenza type B. Stabilizers - albumin solution (1.5-2 mg / ml), preservative - merthiolate (80-100 μg / Ml). Liquid in ampoules of 1 ml (2 doses) and in bottles of 20 ml (40 doses) and 50 ml (100 doses). It can be equipped with disposable syringes.

Characteristic

The inactivated purified and concentrated influenza virus of types A1, A2 and B, derived from the virus-containing allonthoid fluid of the chick embryo. The vaccine has a high degree of purification from ovalbumin (ovalbumin is not more than 0.09 μg / ml). The vaccine is prepared from the actual strains proposed by WHO for this epidemic season.

Pharmachologic effect

Mode of action - Immunostimulating.

Forms immunity to influenza viruses.

Indications of the drug Vaccinum grypposum inactivatum fluidum eluatum-centrifugatum

Influenza, postgrippoznye complications (prevention), alleviating the course of the disease in children older than 7 years and adults.

Contraindications

For parenteral administration: hypersensitivity, acute infectious and non-infectious diseases; Chronic diseases in the stage of exacerbation, diffuse connective tissue diseases, adrenal diseases, hereditary and degenerative diseases of the nervous system, allergic diseases; With intranasal administration: hypersensitivity, chronic rhinitis, acute infectious and non-infectious diseases, exacerbation of chronic diseases. Age (up to 7 years).

Application of pregnancy and breastfeeding

Not vaccinated.

Side effects

With parenteral administration: fever, malaise, headache, congestion, puffiness, very rarely - limited infiltrates; When intranasal - increased fever, malaise, headache.

Dosing and Administration

SC, single by 0.5 ml in the area of the outer surface of the shoulder a few centimeters below the shoulder joint.

Intranasally, 0.5 ml (0.25 ml per each nasal passage) twice with an interval of 21-28 days (the extension of the interval for 1-2 weeks is permissible).

Precaution measures

After the introduction, it is necessary to observe the vaccinated for 30 minutes (the possibility of developing allergic reactions). Preparations should be made for anti-shock therapy. The preparation is not suitable for use in ampoules with broken integrity and marking, with changing physical properties (turbidity, intense staining, presence of non-breaking flakes), expired shelf life, improper storage.

Storage conditions of the drug Vaccinum grypposum inactivatum fluidum eluatum-centrifugatum

At a temperature of 2-8 ° C (do not freeze).

Keep out of the reach of children.

The shelf life of the drug Vaccinum grypposum inactivatum fluidum eluatum-centrifugatum

1 year.

Do not use beyond the expiration date printed on the package.